手法を比較

	Wellsスコア (DVT)	CHA₂DS₂-VAScスコア	CURB-65 肺炎重症度スコア
分野	臨床評価	臨床評価	臨床評価
系統	Process / pipeline	Process / pipeline	Process / pipeline
提唱年	1994	2010	2003
提唱者	Philip S. Wells	Gregory Y. H. Lip, Robby Nieuwlaat, et al.	W. Staniford Lim, et al.
種類	Venous thromboembolism risk stratification	Atrial fibrillation stroke risk stratification	Community-acquired pneumonia severity assessment
原典	Wells, P. S., Hirsh, J., Anderson, D. R., et al. (1994). A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography. Archives of Internal Medicine, 154(13), 1541-1546.	Lip, G. Y., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. (2010). Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest, 137(2), 263-272.	Lim, W. S., van der Eerden, M. M., Laing, R., et al. (2003). Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax, 58(5), 377-382.
別名	Wells DVT Score, DVT Wells	CHA2DS2VASc, Atrial fibrillation stroke risk	CURB-65, Pneumonia severity
関連	3	3	3
概要	The Wells score, developed by Wells et al. in 1994, is a clinical prediction rule that stratifies patients into low, intermediate, or high pretest probability of deep vein thrombosis (DVT). It combines seven clinical features to guide diagnostic testing decisions and reduce unnecessary imaging in suspected DVT patients.	The CHA₂DS₂-VASc score, developed by Lip, Nieuwlaat, and colleagues in 2010, is a 9-point risk stratification tool for predicting annual stroke and systemic thromboembolism risk in patients with atrial fibrillation. It is the recommended score by major cardiology guidelines for guiding anticoagulation decisions.	CURB-65, derived and validated by Lim et al. in 2003, is a 5-point severity of illness score for community-acquired pneumonia (CAP). It assesses confusion, urea nitrogen, respiratory rate, blood pressure, and age ≥65 years to stratify mortality risk and guide admission and treatment decisions.